Brought to you by 
Kite Pharma completes $35mm Series A round
28 May 2014
Executive Summary
Kite Pharma Inc. (targeted immunotherapeutics for cancer) raised $35mm through its Series A round. New investor Alta Partners participated, along with all returning major backers including company executive chairman Arie Belldegrun, MD, Pontifax, Commercial Street Capital, and individual investors David Bonderman and Michael Milken. Alta and Pontifax will take seats on Kite's board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kite Pharma completes $35mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice